Amgen Sued On US Stelara Biosimilar After Providing May 2023 Intent

Janssen Alleges Compound And UC Patents Infringed By ABP 654 Biosimilar

 
• By Dean Rudge
  
Amgen logo sign hanging on the office building in Rotkreuz, Switzerland
Amgen targets ustekinumab among the next wave • Source: Alamy/Marlon Trottmann
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products